Kenji Nakano1, Yukiko Sato2, Tohru Sasaki3, Wataru Shimbashi3, Hirofumi Fukushima3, Hiroyuki Yonekawa3, Hiroki Mitani3, Kazuyoshi Kawabata3, Shunji Takahashi1. 1. a Department of Medical Oncology , Cancer Institute Hospital of the Japanese Foundation for Cancer Research , Tokyo , Japan ; 2. b Department of Pathology , Cancer Institute Hospital of the Japanese Foundation for Cancer Research , Tokyo , Japan ; 3. c Department of Head and Neck Surgery , Cancer Institute Hospital of the Japanese Foundation for Cancer Research , Tokyo , Japan.
Abstract
BACKGROUND: A standard chemotherapy for recurrent/metastatic salivary gland cancers has not been established. Combination chemotherapy of carboplatin and paclitaxel should be evaluated as a treatment option. METHODS: This study retrospectively reviewed salivary gland cancer patients who received combination chemotherapy of carboplatin and paclitaxel. The differences in objective responses and in the prognoses according to the different pathological diagnoses were evaluated. RESULTS: A total of 38 patients were enrolled in the study; of them, 18 had salivary duct carcinomas (SDCs), nine had adenoid cystic carcinomas (ACCs), and 11 had other pathological diagnoses. Objective responses were observed in 15 (39%) patients. The median progression-free survival (PFS) was 6.5 months, and the median overall survival (OS) was 26.5 months. ACC patients had relatively low response rates (9%), but there were no significant differences in PFS or OS compared to other sub-types. The treatment was well tolerated, with few adverse events. CONCLUSION: Salivary gland cancer patients showed a moderate clinical response to the combination chemotherapy of carboplatin and paclitaxel. The objective response rates differed according to the pathological diagnoses, but there were no significant differences in prognoses.
BACKGROUND: A standard chemotherapy for recurrent/metastatic salivary gland cancers has not been established. Combination chemotherapy of carboplatin and paclitaxel should be evaluated as a treatment option. METHODS: This study retrospectively reviewed salivary gland cancerpatients who received combination chemotherapy of carboplatin and paclitaxel. The differences in objective responses and in the prognoses according to the different pathological diagnoses were evaluated. RESULTS: A total of 38 patients were enrolled in the study; of them, 18 had salivary duct carcinomas (SDCs), nine had adenoid cystic carcinomas (ACCs), and 11 had other pathological diagnoses. Objective responses were observed in 15 (39%) patients. The median progression-free survival (PFS) was 6.5 months, and the median overall survival (OS) was 26.5 months. ACC patients had relatively low response rates (9%), but there were no significant differences in PFS or OS compared to other sub-types. The treatment was well tolerated, with few adverse events. CONCLUSION:Salivary gland cancerpatients showed a moderate clinical response to the combination chemotherapy of carboplatin and paclitaxel. The objective response rates differed according to the pathological diagnoses, but there were no significant differences in prognoses.
Authors: Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao Journal: Cancer Cytopathol Date: 2020-05-18 Impact factor: 5.284
Authors: Ann-Jean C C Beck; Peter J F M Lohuis; Abrahim Al-Mamgani; Laura A Smit; Willem M C Klop Journal: Eur Arch Otorhinolaryngol Date: 2018-05-21 Impact factor: 2.503
Authors: Victor T G Lin; Lisle M Nabell; Sharon A Spencer; William R Carroll; Shuko Harada; Eddy S Yang Journal: J Natl Compr Canc Netw Date: 2018-10 Impact factor: 11.908
Authors: Eline Boon; Wim van Boxtel; Jan Buter; Robert J Baatenburg de Jong; Robert J J van Es; Miranda Bel; Edward Fiets; Sjoukje F Oosting; Marije Slingerland; Ann Hoeben; Margot E T Tesselaar; Marianne A Jonker; Uta E Flucke; Winette T A van der Graaf; Carla M L van Herpen Journal: Head Neck Date: 2017-12-22 Impact factor: 3.147